“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl
Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology company Ypsomed could include the supply of…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.
-
-
Amneal files again for FDA approval of first dihydroergotamine autoinjector
Amneal Pharmaceuticals has submitted another new drug application (NDA) for its dihydroergotamine (DHE) prefilled syringe autoinjector to treat tough-to-treat headaches,…
-
FDA’s Marks says RFK Jr dialogue gives chance to have “lies debunked” on vaccines
The US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) director has said that a dialogue…
-
KM Biologics’ mpox vaccine approved for emergency use by WHO
The World Health Organization (WHO) has listed KM Biologics' mpox vaccine for emergency use, marking the second shot approved by…
-
Wes Streeting says patients should view data sharing ‘the same as taxes’
UK Secretary of Health and Social Care Wes Streeting has placed data at the heart of the government’s plan to…
-
BMS CFO backs “resilient” pharma industry amid RFK’s impending governance
Following US President-elect Donald Trump's announcement that Robert F Kennedy (RFK) Jr will be appointed as head of the Department…
-
Does Southeast Asia have a growing role in vaccine development?
Seoul will trade gatherings at its famous royal palaces for meetings at two key clinical trial events to be hosted…
-
AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership
AstraZeneca has exercised an option to license a cell therapy from Quell Therapeutics, resulting in a $10m milestone payment heading…
-
Bavarian Nordic shares sink by 12% after mpox sales slump in Q3
Bavarian Nordic has already secured a sizeable portion of revenue for 2025 through orders for its mpox/smallpox vaccine, but financial…
-
Metsera raises $215m in Series B round for weight loss candidates
Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its…